Literature DB >> 20860366

New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation.

Oula C Mansour1, Benny J Evison, Brad E Sleebs, Keith G Watson, Abraham Nudelman, Ada Rephaeli, Damian P Buck, J Grant Collins, Rebecca A Bilardi, Don R Phillips, Suzanne M Cutts.   

Abstract

Mitoxantrone is an anticancer agent that acts as a topoisomerase II poison, however, it can also be activated by formaldehyde to form DNA adducts. Pixantrone, a 2-aza-anthracenedione with terminal primary amino groups in its side chains, forms formaldehyde-mediated adducts with DNA more efficiently than mitoxantrone. Molecular modeling studies indicated that extension of the "linker" region of anthracenedione side arms would allow the terminal primary amino greater flexibility and thus access to the guanine residues on the opposite DNA strand. New derivatives based on the pixantrone and mitoxantrone backbones were synthesized, and these incorporated primary amino groups as well as extended side chains. The stability of DNA adducts increased with increasing side chain length of the derivatives. A mitoxantrone derivative bearing extended side chains (7) formed the most stable adducts with ∼100-fold enhanced stability compared to mitoxantrone. This finding is of great interest because long-lived drug-DNA adducts are expected to perturb DNA-dependent functions at all stages of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20860366     DOI: 10.1021/jm901894c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.

Authors:  Oula C Mansour; Abraham Nudelman; Ada Rephaeli; Don R Phillips; Suzanne M Cutts; Benny J Evison
Journal:  Cancer Chemother Pharmacol       Date:  2022-04-23       Impact factor: 3.288

2.  Approved Anti-cancer Drugs Target Oncogenic Non-coding RNAs.

Authors:  Sai Pradeep Velagapudi; Matthew G Costales; Balayeshwanth R Vummidi; Yoshio Nakai; Alicia J Angelbello; Tuan Tran; Hafeez S Haniff; Yasumasa Matsumoto; Zi Fu Wang; Arnab K Chatterjee; Jessica L Childs-Disney; Matthew D Disney
Journal:  Cell Chem Biol       Date:  2018-06-28       Impact factor: 8.116

3.  Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.

Authors:  Dennis P A Wander; Sabina Y van der Zanden; Gijsbert A van der Marel; Herman S Overkleeft; Jacques Neefjes; Jeroen D C Codée
Journal:  J Med Chem       Date:  2020-10-16       Impact factor: 7.446

Review 4.  DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.

Authors:  Ida Casorelli; Cecilia Bossa; Margherita Bignami
Journal:  Int J Environ Res Public Health       Date:  2012-07-27       Impact factor: 3.390

5.  Cellular antioxidative, cytotoxic, and antileishmanial activities of Homalium letestui.

Authors:  Jude Efiom Okokon; Ahsana Dar Farooq; Mohammed Iqbal Choudhary
Journal:  Avicenna J Phytomed       Date:  2013
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.